title: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
abstract: Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model. IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-gamma secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
authors.affiliation: Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
authors.forename: J
authors.initials: J
authors.lastname: Vieweg
authors.forename: F M
authors.initials: FM
authors.lastname: Rosenthal
authors.forename: R
authors.initials: R
authors.lastname: Bannerji
authors.forename: W D
authors.initials: WD
authors.lastname: Heston
authors.forename: W R
authors.initials: WR
authors.lastname: Fair
authors.forename: B
authors.initials: B
authors.lastname: Gansbacher
authors.forename: E
authors.initials: E
authors.lastname: Gilboa
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000818:Animals; D002455:Cell Division; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D007700:Kinetics; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D051381:Rats; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D007371:Interferon-gamma